OBJECTIVES: To assess the clinical implications of autoantibodies directed against different parts of the Mi-2 beta autoantigen in patients with myositis. METHODS: A systematic assessment of the clinical, laboratory, and histological characteristics of 48 anti-Mi-2 positive patients from six European centres was made. Anti-Mi-2 autoantibodies were determined with an ELISA using four overlapping fragments spanning the entire amino acid sequence of the autoantigen. Data were compared with results for a large group of anti-Mi-2 negative patients with myositis published previously. RESULTS: Anti-Mi-2 autoantibodies were found in dermatomyositis, polymyositis, and inclusion body myositis. In general, myositis with anti-Mi-2 autoantibodies was characterised by relatively mild disease, sometimes accompanied by extra-muscular symptoms, including arthralgia, arthritis, Raynaud's phenomenon, and interstitial lung disease. Cardiac disease was not seen, and treatment response was fair. No differences were found between patients with autoantibodies to different fragments of the Mi-2 beta antigen, except for a potentially increased risk of cancer in patients with antibodies directed to the N-terminal fragment of the autoantigen. CONCLUSIONS: Anti-Mi-2 autoantibodies are not a marker of a specific subtype of myositis. No significant differences between patients with autoantibodies to different fragments of the Mi-2 beta autoantigen are found, with the possible exception of an increased risk of cancer in patients with antibodies to the N-terminal fragment.
OBJECTIVES: To assess the clinical implications of autoantibodies directed against different parts of the Mi-2 beta autoantigen in patients with myositis. METHODS: A systematic assessment of the clinical, laboratory, and histological characteristics of 48 anti-Mi-2 positive patients from six European centres was made. Anti-Mi-2 autoantibodies were determined with an ELISA using four overlapping fragments spanning the entire amino acid sequence of the autoantigen. Data were compared with results for a large group of anti-Mi-2 negative patients with myositis published previously. RESULTS: Anti-Mi-2 autoantibodies were found in dermatomyositis, polymyositis, and inclusion body myositis. In general, myositis with anti-Mi-2 autoantibodies was characterised by relatively mild disease, sometimes accompanied by extra-muscular symptoms, including arthralgia, arthritis, Raynaud's phenomenon, and interstitial lung disease. Cardiac disease was not seen, and treatment response was fair. No differences were found between patients with autoantibodies to different fragments of the Mi-2 beta antigen, except for a potentially increased risk of cancer in patients with antibodies directed to the N-terminal fragment of the autoantigen. CONCLUSIONS: Anti-Mi-2 autoantibodies are not a marker of a specific subtype of myositis. No significant differences between patients with autoantibodies to different fragments of the Mi-2 beta autoantigen are found, with the possible exception of an increased risk of cancer in patients with antibodies to the N-terminal fragment.
Authors: R Brouwer; G J Hengstman; W Vree Egberts; H Ehrfeld; B Bozic; A Ghirardello; G Grøndal; M Hietarinta; D Isenberg; J R Kalden; I Lundberg; H Moutsopoulos; P Roux-Lombard; J Vencovsky; A Wikman; H P Seelig; B G van Engelen ; W J van Venrooij Journal: Ann Rheum Dis Date: 2001-02 Impact factor: 19.103
Authors: I Hausmanowa-Petrusewicz; E Kowalska-Oledzka; F W Miller; M Jarzabek-Chorzelska; I N Targoff; M Blaszczyk-Kostanecka; S Jablonska Journal: Arthritis Rheum Date: 1997-07
Authors: C L Hill; Y Zhang; B Sigurgeirsson; E Pukkala; L Mellemkjaer; A Airio; S R Evans; D T Felson Journal: Lancet Date: 2001-01-13 Impact factor: 79.321
Authors: G J D Hengstman; R Brouwer; W T M Vree Egberts; H P Seelig; P J H Jongen; W J van Venrooij; B G van Engelen Journal: J Neurol Date: 2002-01 Impact factor: 4.849
Authors: L A Love; R L Leff; D D Fraser; I N Targoff; M Dalakas; P H Plotz; F W Miller Journal: Medicine (Baltimore) Date: 1991-11 Impact factor: 1.889
Authors: Andrew L Mammen; Livia A Casciola-Rosen; John C Hall; Lisa Christopher-Stine; Andrea M Corse; Antony Rosen Journal: Arthritis Rheum Date: 2009-12
Authors: Rohit Aggarwal; Andriy Bandos; Ann M Reed; Dana P Ascherman; Richard J Barohn; Brian M Feldman; Frederick W Miller; Lisa G Rider; Michael O Harris-Love; Marc C Levesque; Chester V Oddis Journal: Arthritis Rheumatol Date: 2014-03 Impact factor: 10.995
Authors: Hector Chinoy; Noreen Fertig; Chester V Oddis; William E R Ollier; Robert G Cooper Journal: Ann Rheum Dis Date: 2007-03-28 Impact factor: 19.103